Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Zealand Pharma A/S ADR stock

Learn how to easily invest in Zealand Pharma A/S ADR stock.

Zealand Pharma A/S ADR is a biotechnology business based in the US. Zealand Pharma A/S ADR shares (ZEAL) are listed on the NASDAQ and all prices are listed in US Dollars. Zealand Pharma A/S ADR employs 345 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Zealand Pharma A/S ADR

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZEAL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Zealand Pharma A/S ADR stock price (NASDAQ: ZEAL)

Use our graph to track the performance of ZEAL stocks over time.

Zealand Pharma A/S ADR shares at a glance

Information last updated 2022-06-24.
Latest market close$13.75
52-week range$9.93 - $34.30
50-day moving average $12.57
200-day moving average $19.90
Wall St. target price$31.86
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.26

Buy Zealand Pharma A/S ADR shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zealand Pharma A/S ADR stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zealand Pharma A/S ADR price performance over time

Historical closes compared with the close of $13.75 from 2022-06-28

1 week (2022-06-22) 0.04%
1 month (2022-05-27) -1.36%
3 months (2022-03-30) -14.33%
6 months (2021-12-30) -37.53%
1 year (2021-06-30) -53.17%
2 years (2020-06-30) -60.71%
3 years (2019-06-28) 21.5241
5 years (2017-06-26) N/A

Zealand Pharma A/S ADR financials

Revenue TTM $301.9 million
Gross profit TTM $173.8 million
Return on assets TTM -31.66%
Return on equity TTM -80.68%
Profit margin 0%
Book value $16.42
Market capitalisation $603.1 million

TTM: trailing 12 months

Zealand Pharma A/S ADR share dividends

We're not expecting Zealand Pharma A/S ADR to pay a dividend over the next 12 months.

Zealand Pharma A/S ADR share price volatility

Over the last 12 months, Zealand Pharma A/S ADR's shares have ranged in value from as little as $9.93 up to $34.3. A popular way to gauge a stock's volatility is its "beta".

ZEAL.US volatility(beta: 1.25)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zealand Pharma A/S ADR's is 1.2531. This would suggest that Zealand Pharma A/S ADR's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Zealand Pharma A/S ADR overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc. ; and Beta Bionics, Inc.

Frequently asked questions

What percentage of Zealand Pharma A/S ADR is owned by institutions?
Currently 1.875% of Zealand Pharma A/S ADR shares are held by institutions.
How many people work for Zealand Pharma A/S ADR?
Latest data suggests 345 work at Zealand Pharma A/S ADR.
When does the fiscal year end for Zealand Pharma A/S ADR?
Zealand Pharma A/S ADR's fiscal year ends in December.
Where is Zealand Pharma A/S ADR based?
Zealand Pharma A/S ADR's address is: Sydmarken 11, Copenhagen, Denmark, 2860
What is Zealand Pharma A/S ADR's ISIN number?
Zealand Pharma A/S ADR's international securities identification number is: US98920Y3045
What is Zealand Pharma A/S ADR's CUSIP number?
Zealand Pharma A/S ADR's Committee on Uniform Securities Identification Procedures number is: 98920Y304

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site